Protein S inherited qualitative deficiency: novel mutations and phenotypic influence.
INTRODUCTION
p.Thr78Met) [5, 6] , in the thrombin sensitive loop (TSR) (p.Arg101Cys) [7] and in the epidermal-growth factor (EGF) like domains, [p.Thr144Asn in EGF1, in EGF2 p.Asp157Gly, p.Cys175Phe, and p.Lys196Glu in EGF2, p.Cys217Tyr, p.Tyr225Cys in EGF3, p.
Ile244-Asp245 del in EGF4] [5, 8, 9, 10] . A substitution in the donor splice site of intron 5 (c.469+5G>A) leading to exon 5 skipping induces full loss of EGF1 [5] . In addition, two natural missense mutations at position 95, p.Gly95Glu and p.Gly95Arg were reported in patients with mild decrease in the PSA/FPS ratio [5] . Type II PS inherited deficiency could be in fact more frequent than generally considered since PS functional assay is performed by a minority of laboratories in the screening for PS deficiency; the reason for measuring FPS level rather than PSA is "historical" due to insufficient specificity of the first generation of commercial PS activity assays. Moreover, no commercial reagent allowing direct PS activity measurement are available. However, it would be important to include searching for type II variants in thrombophilia screening if these variants do increase risk of thrombosis.
The two objectives of the present study were: 1) to assess the usefulness of Staclot PS (Stago, Asnières, France) for screening for type II inherited deficiency; this assay is based on modified activated partial thromboplastin time (APTT). Diluted patient plasma is added to PS-depleted plasma in the presence of purified APC and factor Va, therefore the assay measures the APC dependent activity of PS; and 2) to gain insight on phenotypical consequences of PROS1 type II mutations. We report the results of PROS1 analyses performed in the whole group of probands with a suspicion of inherited qualitative PS abnormality studied in our laboratory between 2000 and 2008 and in relatives. We also report the results of thrombin generation tests (TGTs) performed by calibrated automated thrombinography (CAT) [11] on plasma from 76 carriers of distinct PROS1 mutations, including 26 with type II defects, and we compare thrombosis history in relatives with type II or type I/III defects.
SUBJECTS AND METHODS

Subjects
Subjects studied were initially referred to specialized French clinical haematology laboratories for thrombophilia screening in the context of unexplained personal or family history of thrombosis. Recording of clinical characteristics of the subjects including objectively confirmed episodes of venous thrombosis (VT) or pulmonary embolism (PE), and screening for biological risk factors for VT (antiphospholipid antibodies, antithrombin, protein C, protein S deficiency, the FV Leiden and the F2 G20210A mutations) were performed in each centre. Family history of VTE was defined by the occurrence of VT in at least one first degree relative. When an inherited PS deficiency was suspected, DNA and plasma samples, when available, were sent to our laboratory for PROS1 genotyping. An informed consent authorizing genetic analyses was obtained from every patient, according to the Helsinki declaration.
Genetic study: In the period 2000-2008, we analyzed PROS1 in 30 probands (14 men, 16 women), mean age 44.7 (extreme values , in whom a PS inherited qualitative deficiency was suspected and 35 relatives from 15 of these kindreds.
Plasma PS activity (PSA) and TPS levels were measured using Staclot PS and Asserachrom TPS reagents (Stago). FPS level was measured using the FPS reagent from Instrumentation Laboratory (Milano, Italy) in two patients and using the Asserachrom FPS kit (Stago) in the others. PS type II inherited deficiency was suspected in probands based on the observation of a persistent decreased or borderline PSA and abnormal PSA/FPS ratio (< or =0.80) in the absence of factors susceptible to induce falsely low Staclot PS level (FVIII>250% [12] , FV Leiden [13] , antiphosholipid antibodies..).
TGTs:
TGTs were performed on plasma from: 26 subjects heterozygous for type II PROS1 mutations and 34 subjects with type I/III mutations previously identified by sequencing, one individual with a Multiplex Ligation-dependent Probe Amplification (MLPA) profile suggesting heterozygosity for a complete deletion of the gene, 15 PS Herleen (Ser501Pro) heterozygous carriers, 7 relatives from these families who did not carry the mutation present in their pedigree. They did not receive hormonal treatment and had no other biological risk for thrombosis. The subjects were selected on their genotype and on availability of plasma samples for TGTs. A last group consisted of 19 "healthy subjects" with no personal history of thrombosis and no biological risk factor for VT, studied in our laboratory during the same period, Symptomatic subjects were studied at distance from thrombosis events, at least 1 month after stopping oral anticoagulant treatment.
All samples for PS assessment and thrombin generation work were taken in the absence of anticoagulant treatment.
PROS1 defects carrying and thrombosis history:
We compared thrombosis history in adult (> 15years old) relatives from all families with PROS1 mutations associated with type II (36 relatives from 9 families) or quantitative PS deficiency (47 relatives from 11 families) and no other risk factor for thrombosis studied in our laboratory between 2000 and 2010, for whom full clinical information was available.
Mutations responsible for quantitative deficiency were premature stop-codons or missense detrimental mutations already described.
PROS1 analysis
In the probands, the exons, the intron-exon boundaries and 700bp of the proximal promoter of the functional gene for PS, PROS1 (GeneID: 5627, MIM#176880) were studied by direct sequencing as previously described [14, 15] . In family members, gene analysis was restricted to the region found abnormal in the proband. Mutations are numbered according to the HUGO recommendations for mutation nomenclature (http://www.hgvs.org) based on the start codon (ATG) of the first translated methionine. Amino-acid numbering according to the ISTH database [5] , based on the mature protein, is obtained by substracting 41 for residues of the mature protein or 42 for residues that belong to signal peptide and propeptide.
Thrombin generation tests
Venous blood was collected on 0.109M sodium citrate in the recruiting centres. Platelet poor plasma was prepared by double-centrifugation for 15mn at 2000-2500g, at temperature between 15 and 22°C, within 2hours from blood sampling, then stored frozen in small aliquots at temperature <-30°C. For every patient, all clotting tests were performed on a unique plasma sample, within 2 hours after thawing. Thrombin generation in the presence or absence of activated protein C (APC) was measured according to the method described by Hemker et al. [11] using the reagents PPP (-a mixture of phospholipids (PL) and tissue factor (TF)-), thrombin calibrator and the fluorogenic substrate FluCa from Thrombinoscope (Maastricht, Netherlands), following the manufacturer's instructions except for the following modification: thrombin generation was triggered by the addition of 20ul PPP reagent to 80ul plasma in the presence of 5ul APC (10ug/ml) (Hyphen Biomed, Neuville s/Oise, France) or 5ul 0.15MNaCl. Fluorescence measurements were performed after addition of 20ul of FluCa. Final concentrations of PL and TF in the mixture were 4.8pM TF and 3.9uM PL. The parameters studied were the area under the curve (endogenous thrombin potential: ETP), the lag time, time to peak (PT), peak height and the start tail (ST), time at which thrombin generation has come to an end. Inter-assay coefficients of variation (CV) calculated on the results obtained for a normal plasma pool in 2 series of respectively 7 and 6 independent runs were <10% for ETP-APC, peak height-APC, ST-APC, PT +/-APC, and 10-20% for the other parameters studied. CV of the ETP -APC/+APC ratio was 15%.
PSA, factor II (FII), FV, FVIII, F-TFPI, TPS, FPS, and fibrinogen level when not previously determined on fresh plasma, were also measured on this plasma sample, using reagents from Stago (Asnières, France). FV level was checked in order to verify that storage did not alter the quality of plasma samples
Statistical analysis of TGT results
Distribution of each parameter was tested for normality and transformed variables were used for non-parametric distributions. Mean levels were given in 
RESULTS
Genetic study
Information concerning thrombosis history, and plasma PS levels in the probands and mutated family members are shown in Table 1 . A personal history of VT was present in 28 probands; P10, asymptomatic, was explored because of a family history of VT; P24 had a history of distal arterial thrombosis in association with a systemic lupus. Other biological risk factors for thrombosis were present in 3 probands (heterozygosity for a detrimental PROC mutation in P22 and for the F2 nt 20210G>A substitution inP24 and 29), but in no relative. Thrombosis antecedents were present in one 1 st degree relative in 9 families, and in 4 relatives in another kindred.
Nineteen different mutations were found in 29 probands and in 28 relatives.
Fifty-three subjects were heterozygotes. Two individuals were homozygotes, and two others were compound heterozygotes. We found 12 mutations [c.143A>G (p.Glu48Gly),
Asn219Ser) ] which, to the best of our knowledge, were not previously reported. We also found 6 previously described detrimental changes No mutation was found in 7 asymptomatic relatives which presented with normal PS levels.
Thrombin generation tests
Relatives non-carrier of PROS1 mutations and healthy subjects were combined in the analyses since no significant differences in descriptive characteristics or TG parameters were found among the subjects.
General characteristics are reported in Table 2 . Age, factor II, FV, FVIII, fibrinogen mean levels were similar among the groups. F-TFPI level was higher in type II than in type I/III deficient patients. As expected, PSA and FPS levels were clearly low in PROS1 type I/III mutation carriers and mildly decreased in PS Herleen carriers. In type II mutation carriers, mean PSA was borderline. PSA/FPS ratio was significantly decreased in patients with type II mutations. Sixty-six among these 102 subjects were asymptomatic.
Multiple regression analysis revealed significant positive influence of FII (r=0.44, <0.001, and r=0.29, p=0.003) and fibrinogen (r=0.39, p=0.002 and r=0.25, p=0.01) on ETP and peak height in the absence of APC; PS (PSA r=-0.23, p=0.02, FPS r=-0.18, p=0.06) and FV (r=0.29, p=0.02) had a mild significant influence on ETP only and FVIII on peak height only (r=0.21, p=0.03). In the presence of APC, ETP and peak height were highly dependent on PS (PSSTA: r= -0.69 p<0.0001, FPS: r=-0.64, p<0.0001) and F-TFPI (r=-0.43, p<0.0001), and a mild influence of FVIII on both parameters was observed (r=0.21, p=0.03).
Overall comparison demonstrated significant inter-group differences for ETP and no significant difference in lag time or start tail. Table 3 shows the influence of PROS1 defects on ETP and peak height. Both the statistical significance and the means were adjusted for age, sex, personal history of VTE, and for FII, fibrinogen, FV and FVIII, which had significant influence on these parameters. ETP in the absence of APC was 20% higher in carriers of PROS1 mutations than in nonmutated subjects, whatever the type of defect. Highly significant differences between type I/III or type II mutation carriers and non-mutated subjects for both ETP and peak height in the presence of APC and for ETP and peak ratios (demonstrating an APC resistance) were observed (p<0.0001). Thrombin generation in the presence of APC was indeed 3 fold higher in patients with PS type I/III deficiency than in PS Herleen carriers or subjects without mutations and 2 fold higher in patients with type II mutations. Significance was lost after adjustment on PSA which explained more than 80% of inter-group differences in the presence of APC, demonstrating that in this condition the effects on TGT are mainly due to PS defects, and 30-60% of intergroup differences, showing a lower contribution, in the absence of APC. Further adjustment on F-TFPI did not change the results. No significant differences between PS Herleen carriers and non mutated subjects were observed. There was no significant difference in TGT parameters between individuals who had suffered VT and those who had not.
PROS1 mutations and thromboembolic history
Characteristics of the relatives studied and incidences of VT events (deep or superficial VT or PE) are given in Table 4 , and event free survival curves for VT are shown in Figure 1 . The 15 non-mutated relatives from the 30 families studied were asymptomatic. Eight among 37 relatives with type I/III mutation and 2 among 21 relatives with type II mutation displayed a thrombosis history. Annual incidence of VT in relatives with type I/III mutation was 0.56 (0.17-0.95). Heterozygosity for a PROS1 type I/III mutation conferred an odds ratio for VT of at least 4.3 (95% CI 0.3-69.0) as compared with the non-mutated relatives from the type I/III group. However, these estimations are not fully reliable due to the absence of VT event among non-carriers.
Incidence was 2 fold lower in relatives with type II mutation [0.24 (0-0.58)]. However, the difference was non significant (p=0.22).
DISCUSSION
The 12 novel mutations, which affect residues 48, 91, 120, 157, 161, 180, 189, 204, or 219 could explain a qualitative deficiency for the following reasons:
Firstly, the affected residues, except Ser 91, are highly conserved in PS among mammalian species.
Secondly, most novel mutations (-except those at positions 204 and 219-) are located in regions of PS (GLA, TSR, EGF1 and 2) known to be crucial for APC cofactor activity [16] [17] [18] [19] . Among these mutations, Glu 48, Ser 91 and Gln 120 are located "at strategic positions". Glu 48 is located in a crucial ω loop of the GLA region involved in interaction of PS with anionic PL surfaces [16] , and Ser 91 is located at a site where cleavage by thrombin leads to PS inactivation [17] . Gln 120 together with Asp 119 and Asp 136 in EGF1 could be part of the principal functional interaction site for APC [20] . A p. Gln 120 Ala variant expressed in vitro and analysed in a TG assay was recently reported to have severely reduced APC cofactor activity [20] .
Residues 204 and 219 are located in EGF3 which has less understood functions.
However, these residues belong to typical Ca2+ binding consensus sequences possibly important for the structural integrity of PS as specific cooperative effect of EGF2 and EGF3 for calcium binding have been demonstrated [21] . Moreover, a p.Glu204Gly PS variant expressed in vitro was previously reported to have decreased anticoagulant function [10] . In addition, functional importance of the EGF domains is supported by previous description of natural mutations associated with type II PS deficiency at positions 144, 157, 175, 196 and 217 [5] .
Thirdly, p.Cys161Arg, p.Ser91Pro and p.Gly180Arg may induce significant modifications of the protein structure due to disruption of a disulfide bridge for the first one or differences in physicochemical characteristics for the others. Five mutations (p.Arg40Leu, p.Gly95Glu p.Thr78Met, p.Arg101Cys, p.Ile244-Asp245 del) had been previously described, and found associated with type II deficiency [5, 7, 22] . p.Arg233Lys was the unique mutation found in probands 22 and 23.
However, as Arg233Lys was previously reported to be a neutral polymorphism [5] , its presence probably does not explain plasma levels.
Absence of mutation was observed in only one proband (P24) in whom an acquired PS abnormality cannot be excluded accounting for the clinical context (systemic lupus), even if no antiphospholipid or anti PS IgG (Zymuphen anti PS IgG, Hyphen BioMed, Neuville s/Oise, France) could be detected.
Finally, mutations possibly explaining decreased PSA/FPS ratios were found in 27 among the 30 probands (90%) studied documenting the usefulness of Staclot PS for type II mutation screening, when applied to probands with no cause of 'false positive" results (i.e FV Leiden, FVIII>250%) [12, 13] . In relatives, the assay was not 100% sensitive as illustrated by the observation of fully normal PSA in 6 among the 27 heterozygotes studied (carriers of Arg40Leu (3), Glu48Gly (1), Arg101Cys (1) or Asn219Ser (1) respectively). However, PSA/FPS ratio was decreased in 3 among them. Possible explanations for "false-negative" results are the following: firstly, the nature of the assay, based on a modified APTT, therefore possibly sensitive to negative as well as positive interferences; secondly, a global increase in PS level due to acquired conditions; thirdly, a genetic origin: phenotypic variability in Thr78Met carriers was previously observed, and explained by the "mild" influence of the mutation on both secretion and function of PS [6] . A mild influence of the mutation could similarly explain phenotypic variability associated with heterozygosity for Arg40Leu or Lys50Glu [5] , or other mutations reported here.
We used thrombinography to gain insight into the influence of type II mutations carrying on procoagulant potential. It was previously reported that CAT monitoring performed at low TF concentration (1pM) in the absence of APC and at high concentration (10-15pM) in the presence of APC are conditions with an optimal sensitivity to the activity of the TFPI/PS system [23, 24] . In such conditions, pooled plasma from heterozygous type I PS deficient individuals generated 3-5 fold more thrombin than normal plasma [25] . In accordance with this finding, in a large group of heterozygous carriers of type I/III mutations, we found a significant APC resistance in TGTs performed at 4.8pM TF, which can be fully explained by PS defects. Whether the risk of VT is increased in PS Herleen heterozygous subjects remains doubtful; the prevalence of the S501P mutation is indeed rather high in healthy populations (around 0.5%) and no significant association was found between PS Herleen carrying and VT [29] . PS Herleen allele may be in fact significantly involved in the occurrence of VT only in individuals who carry other genetic traits [28, 30] . We did not observe any influence of PS Herleen on TGT parameters except on ETP-APC, supporting no more than a mild influence on procoagulant potential.
To the best of our knowledge, the influence of type II mutations on CAT parameters has not been studied yet. Our finding of a significant 2-fold increased ETP+APC and ETP ratio in carriers of type II mutations compared to subjects with no defect or PS Herleen carriers is consistent with a procoagulant phenotype and suggests that type II inherited deficiency may be a risk factor for VT.
Recent studies on risk of a first VT event in carriers of PS type I/III inherited deficiency reported annual incidences ranging from 0.27 to 1.5% in line with our own result [31] [32] [33] [34] [35] . To the best of our knowledge, the risk of VT associated with type II defects has not yet been studied. In the present study, no significant influence on the risk of VT could be demonstrated. However, the number of relatives investigated was small and should be increased for obtaining more reliable estimate of the risk. 
